ArticleProceedings of the National Academy of Sciences of the United States of America2017
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02601716 (Clinical Trial of PfSPZ Vaccine Administered by Direct Venous Inoculation), which is not on this map. Cited by 149 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 1 pooled it
31.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial of PfSPZ Vaccine Administered by Direct Venous Inoculation: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults
Who cites it
149 citing papers in PubMed, 1 synthesis or guideline pooled it, 251 citations in OpenAlex.
- Pooled it
- Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine.JCI insight · 2024Trial
- Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults.The Journal of clinical investigation · 2024Trial
- Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults.The American journal of tropical medicine and hygiene · 2023Trial
- A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria.Science translational medicine · 2022Trial
- Trial
- Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.The Lancet. Infectious diseases · 2022Trial
- Repeat controlled human malaria infection of healthy UK adults with blood-stageFrontiers in immunology · 2022Trial
- Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.Nature medicine · 2021Trial
- Trial
- Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.Nature communications · 2021Trial
- Trial
- Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans.Cell reports · 2021Trial
- Trial
- Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Trial
- Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Safety and Differential Antibody and T-Cell Responses to theThe American journal of tropical medicine and hygiene · 2019Trial
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 4 institutions in 1 country.
Kirsten E LykeCenter for Vaccine Development and Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD 21201.
Andrew S IshizukaVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.ORCID 0000-0002-3024-7536
Andrea A BerryCenter for Vaccine Development and Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD 21201.
Sumana ChakravartySanaria Inc., Rockville, MD 20850.
Adam DeZureVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Mary E EnamaVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Eric R JamesSanaria Inc., Rockville, MD 20850.
Peter F BillingsleySanaria Inc., Rockville, MD 20850.
Anusha GunasekeraSanaria Inc., Rockville, MD 20850.
Anita ManojSanaria Inc., Rockville, MD 20850.
Minglin LiSanaria Inc., Rockville, MD 20850.
Adam J RubenSanaria Inc., Rockville, MD 20850.
Tao LiSanaria Inc., Rockville, MD 20850.
Abraham G EappenSanaria Inc., Rockville, MD 20850.
Richard E StaffordSanaria Inc., Rockville, MD 20850.
Natasha KcSanaria Inc., Rockville, MD 20850.
Tooba MurshedkarSanaria Inc., Rockville, MD 20850.
Floreliz H MendozaVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Ingelise J GordonVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Kathryn L ZephirVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
LaSonji A HolmanVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Sarah H PlummerVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Cynthia S HendelVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Laura NovikVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Pamela J M CostnerVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Jamie G SaundersVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Nina M BerkowitzVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Barbara J FlynnVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Martha C NasonBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Lindsay S GarverEntomology Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910.
Matthew B LaurensCenter for Vaccine Development and Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD 21201.
Christopher V PloweCenter for Vaccine Development and Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD 21201.
Thomas L RichieSanaria Inc., Rockville, MD 20850.
Barney S GrahamVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Mario RoedererVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
B Kim Lee SimSanaria Inc., Rockville, MD 20850.
Julie E LedgerwoodVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Stephen L HoffmanSanaria Inc., Rockville, MD 20850.
Robert A SederVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; rseder@mail.nih.gov.
National Institutes of Health · USSanaria · USUniversity of Maryland, Baltimore · USWalter Reed Army Institute of Research · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MDevelopment of Pre-Erythrocytic Malaria Vaccines and antibodiesZIAAI005107 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SEDER, ROBERT A · 2010 to 2025
$20.7MPlasmodium Falciparum Whole Sporozoite Malaria VaccineR44AI055229 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2005 to 2015
$10.0MUniversal Attenuated Sporozoite Vaccine and Challenge SystemR44AI058375 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2006 to 2018
$9.9MIMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINER44AI058499 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2008 to 2014
$6.0MProtein microarray antibody responses to P. falciparum in a human challenge modelK23AI125720 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2017 to 2021
$915kNIAID NIH HHS K23 AI125720NIAID NIH HHS R44 AI055229NIAID NIH HHS R44 AI058375NIAID NIH HHS R44 AI058499NIGMS NIH HHS T32 GM007171
Abstract
A live-attenuated malaria vaccine,
Indexed as
AdolescentAdultFemaleHealthy VolunteersHumansMalaria, FalciparumMalaria VaccinesMaleMiddle AgedPlasmodium falciparumSporozoitesT-LymphocytesVaccines, AttenuatedMalaria VaccinesVaccines, Attenuatedlive-attenuated vaccinemalariaplasmodiumsporozoiteT-cell immunology
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02601716ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.